Effects of Zoledronic Acid on Proliferation and Synergy with Cytotoxic Agents in Nasopharyngeal Carcinoma Cell Lines

Bhagirath Ghimire,Zhang Li,Zhou Xing,Li Su,Xue Hou,Peiyao Peng

IF: 11.2

2007-01-01

Cancer Research

Abstract:AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 2410 Background: Recent evidence suggests that nitrogen-containing bisphosphonates (N-BPs) inhibits proliferation at clinically achievable concentrations and have shown the potential to become attractive agents for cancer therapy. Zoledronic acid (ZOL) is a new generation N-BP that has demonstrated the broadest clinical activity of all the available bisphosphonates. N-BPs exert their effects on osteoclasts and tumor cells by inhibiting a key enzyme in the mevalonate pathway, farnesyl diphosphate synthase, thus preventing protein prenylation and activation of intracellular signaling proteins such as Ras. In addition, ZOL exerts synergistic antitumor activity when combined with other anticancer agents like cisplatin, taxoids, doxorubicin and imatinib. Although ZOL has exhibited antiproliferative and synergistic antitumor effects in different cells lines, effects on nasopharyngeal cancer (NPC) cell lines have never been reported. Methods: In the first part of this study we investigated the antiproliferative effects of ZOL and cisplatin as single agents on four NPC cell lines CNE-1, CNE-2, SUNE-1 and 5-8F. Cell proliferation was determined by the MTT assay. NPC cell lines were seeded in a flat-bottomed 96-well plate at 10+4 in 200µl of medium per well and incubated with various concentrations of the test agents for 72 hours. IC50 values for each cell line were obtained using the non-linear regression program CalcuSyn. After an IC50 had been obtained the IC10 values for ZOL and cisplatin were calculated from the IC50 curve of each of the four cell lines. A total of 8x4 wells were seeded in a flat-bottomed 96-well plate at 10+4 cells in 200µl of medium per well, the first two rows were used as control, in the 3rd and 4th row, ZOL and cisplatin in combination were added , in the 5th and 6th rows ZOL and in the 7th and 8th rows cisplatin were added. In all the experiments, a concentration equivalent to IC10 for the particular cell lines was added . The entire plate was incubated for a total of 72 hours and the absorbance was measured at a wavelength of 540nm in a microplate reader. Results: This study demonstrates that the third-generation N-BP, ZOL, has a direct antiproliferative effect and augments the effects of cisplatin against NPC cell lines as shown in Tables 1 and Tables 2. Conclusion: ZOL has potent anti-NPC effects as a single agent in vitro, and augmented the effects of cisplatin. Thus, ZOL plus cisplatin may be a promising therapeutic strategy for NPC. The efficacy and safety of ZOL therapy for NPC should be verified in early phase clinical trials.